A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience

Phase 2 Completed 27 enrolled AstraZeneca

RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of the study is to estimate what effect 4 different doses of AZD3355 will have on the number of reflux episodes, in patients who have GERD and still experience symptoms despite proton pump inhibitor (PPI) treatment.

Timeline

Start: 2009-12
Primary completion: 2010-05
Completion: 2010-05

Publications

Miner PB Jr, Silberg DG, Ruth M, Miller F, Pandolfino J. Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study. BMC Gastroenterol. 2014 Nov 18;14:188. doi: 10.1186/1471-230X-14-188.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	lesogaberan	Small molecule	30 mg	Oral
Subject	lesogaberan	Small molecule	90 mg	Oral
Subject	lesogaberan	Small molecule	120 mg	Oral
Subject	lesogaberan	Small molecule	240 mg	Oral

A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience

Summary

Timeline

Publications

Drugs

Indications